๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Candidate chemoprevention agents in clinical trials

โœ Scribed by Waun Ki Hong

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
93 KB
Volume
53
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Colon cancer chemoprevention: Clinical d
Colon cancer chemoprevention: Clinical development of aspirin as a chemopreventive agent
โœ Krishnan, Koyamangalath; Ruffin, Mack T.; Brenner, Dean E. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 81 KB ๐Ÿ‘ 2 views

We have studied aspirin as a potential chemopreventive for colorectal cancer, completing Phase I studies on aspirin pharmacology and potential biomarker assays (prostaglandins, PGE 2 and PGF 2โฃ and cyclooxygenase modulation) in normal human subjects. These studies have determined the optimal dose of

Progress in cancer chemoprevention: Agen
Progress in cancer chemoprevention: Agents
โœ Charles W. Boone; Ming You ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 22 KB ๐Ÿ‘ 2 views

Collaborative chemoprevention projects between the United States (US), China, Korea, and Japan are desirable because each country contributes significant specialized resources and expertise, making the projects proceed more rapidly than they could in any one country alone. The US offers experience i

Criteria for implementation of large and
Criteria for implementation of large and multiagent clinical chemoprevention trials
โœ Frank L. Meyskens Jr. ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 79 KB

If one were to wait for the perfect set of experimental results before launching a multi-agent chemoprevention or large risk reduction study, the trial would never be launched. On the other hand, non-scientific considerations have led to the premature launching of at least three prominent studies (C